Maggie Tibbitt

Articles

Heavily Pretreated Patients With Relapsed/Refractory Myeloma Achieve Encouraging Responses With Teclistamab Plus Daratumumab

Maggie Tibbitt

May 20th 2022

An expert with the phase 1b TRIMM-2 trial underscores the significance and findings for patients with multiple myeloma.

Upifitamab Rilsodotin May Be an Answer to the Question of Platinum-Resistant Recurrent Ovarian Cancer

Upifitamab Rilsodotin May Answer Questions in Platinum-Resistant Recurrent Ovarian Cancer

Maggie Tibbitt

February 2nd 2022

An expert from Arizona Oncology discusses the unmet need for agents to address recurrent ovarian cancer and how upifitamab rilsodotin, an antibody-drug conjugate with promising preclinical and clinical data, may play into the treatment paradigm.

Patients With HER2+ Metastatic Breast Cancer Experience Consistent PFS Benefit With Trastuzumab Deruxtecan

Maggie Tibbitt

January 14th 2022

An expert discusses the implications of a subgroup analysis of the DESTINY-BREAST03 trial, which highlighted the efficacy of trastuzumab deruxtecan in HER2-positive metastatic breast cancer.

Olaparib Plus Temozolomide Induces Promising Response Duration in Uterine Leiomyosarcoma

Maggie Tibbitt

January 8th 2022

The use of PARP inhibitor olaparib in conjunction with temozolomide may be an effective treatment for patients with advanced uterine leiomyosarcoma whose tumors harbor a BRCA-like phenotype.